Core Insights - The company transitioned from a partnered model with Ascensia to a fully integrated developer, manufacturer, and direct seller to gain agility and eliminate revenue sharing [1] Financial Performance - Achieved 60% year-over-year revenue growth in 2025, driven by a 103% increase in new patient starts following the U.S. launch of Eversense 365 [1] - Improved gross margins to over 50% by year-end 2025, aided by the shift toward a consignment sales model and higher-margin 365-day sensor sales [1] Market Expansion - Expanded the domestic prescriber base by over 80% year-over-year, reflecting increased clinical confidence in the long-term implantable CGM system [1] Product Integration - Successfully integrated with Sequel's twiist automated insulin delivery system, marking the company's first entry into the Type 1 pump-integrated market [1] Operational Improvements - Internalized the EON Care Group inserter network to address clinical bottlenecks, with approximately 25% of U.S. insertions now performed by this in-house team [1]